Pipeline

Powered by Molecule Pro

Program
Modality
Indication
Discovery
Optimization
IND-Enabling
Clinical
Partner
Wholly Owned
MRANK001
GPCR
Undisclosed
Potential Best-in-Class
MRANK023
Undisclosed
Undisclosed
MRANK002
Undisclosed
Undisclosed
MRANK603
Undisclosed
Undisclosed
Potential First-in-Class
Co-developed
3 Programs
Undisclosed
Undisclosed
Public Traded Biotech
8 Programs
Undisclosed
Undisclosed
Design as a Service
EMRANK001
Allosteric Inhibitor
Oncology
PCC delivered
Public Traded Biotech
EMRANK189
Undisclosed
Undisclosed
Lead delivered
Public Traded Biotech